Investor Presentation - TechKnow Invest Roadshow
Filed with ASX · · 19 pages · English
Summary by 6ix AI
The presentation outlines the market opportunity, emphasizing a faster and lower-risk path to market for their injectable formulation of Quetiapine. It highlights the challenges of current treatments and the advantages of their proprietary formulation in clinical settings. The document also discusses the company's executive team and their expertise in drug development and commercialization.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
In the deck
Story so far
Earlier from Patrys
- Appendix 4C - Quarterly - 30 June 2026
- Patrys Secures 50% Revenue Share in IP Commercialisation
- Patrys advances RLS-2202 toward Phase 1 Clinical Trial
- Appendix 4C - Quarterly - 31 March 2026
- $3.2 million Placement to Advance Clinical Trials
Later from Patrys
- Ethics Approval Secured for Phase 1A Clinical Trial
- Appendix 4E - Preliminary Final Report
- PAB Establishes Clinical Advisory Committee
- First Participants Dosed in RLS-2202 Phase 1A Clinical Trial
- Appendix 4G and Corporate Governance Statement
Follow Patrys into a list and get an email when it puts out news.
Follow Patrys